Real-world treatment utilization in adults with chronic inflammatory demyelinating polyneuropathy in the United States

Key Points

• Patients with chronic inflammatory demyelinating polyneuropathy often receive steroids and immunoglobulin (Ig) as treatments, indicating standard care patterns.
• A large portion of Ig users continues treatment long-term, with overlapping steroids usage found in many cases, heightening patient burden.
• Analysis of treatment utilization across the United States highlights the combination of therapies in CIDP management.
• The findings imply a significant impact on patient quality of life due to ongoing treatment needs and potential side effects.